Hard on the heels of Eli Lilly's ($LLY) decision to abandon insulin peglispro, rival Novo Nordisk ($NVO) is moving ahead with its faster-acting insulin aspart, filing for FDA approval of the mealtime insulin for diabetes. The insulin was studied in some 2,100 adults with Type 1 and Type 2 diabetes. Novo filed in the EU last week. "Today's filing of faster-acting insulin aspart is a step forward in strengthening our mealtime insulin offerings for patients who require mealtime blood sugar control," said Dr. Todd Hobbs, U.S. chief medical officer of Novo Nordisk. "Faster-acting insulin aspart underscores our continued commitment to developing new treatment options for these patients. We look forward to working closely with the FDA on the submission and are focused on bringing the next generation of our mealtime insulin to market." Release